GLP-1 Agonists Drug Pipeline Report 2025: Comprehensive Analysis of 100+ Drugs and 50+ Companies - ResearchAndMarkets.com

The GLP-1 agonists drug pipeline analysis report includes insights into over 100 pipeline drugs and 50+ companies. The report covers various aspects of these drugs, including their efficacy and safety outcomes, adverse effects, and alignment with treatment guidelines. GLP-1 agonists are primarily used for type 2 diabetes treatment and have shown cardiovascular benefits. The focus on weight management and cardiometabolic health is expected to drive market growth in the coming years.

The GLP-1 agonists drug pipeline analysis report, recently added to ResearchAndMarkets.com, offers comprehensive insights into the growing market driven by rising diabetes and obesity rates. This report covers over 100 pipeline drugs and 50+ companies, providing a strategic overview of the latest and future landscape of treatments for GLP-1 agonists.

GLP-1 agonists are a class of drugs that mimic the glucagon-like peptide-1 (GLP-1) hormone, which regulates blood sugar and appetite. These agents stimulate insulin secretion, suppress glucagon release, and slow gastric emptying, making them widely used in type 2 diabetes treatment and weight management. The report includes an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with GLP-1 agonists treatment guidelines to ensure optimal care practices.

Key players like Eli Lilly are contributing to market expansion and investment in metabolic health. The GLP-1 agonists pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with GLP-1 agonists treatment guidelines to ensure optimal care practices. They are widely used in type 2 diabetes treatment and have shown significant cardiovascular benefits. GLP-1 agonist therapeutic products, such as Semaglutide and Tirzepatide, are advancing with dual and triple agonist mechanisms. The focus on weight management and cardiometabolic health is expected to drive substantial market growth in the coming years.

PolyPid Ltd., a late-stage biopharma company, has unveiled its long-acting GLP-1 receptor agonists delivery platform, which aims to subcutaneously release GLP-1 for approximately 60 days, significantly longer than current weekly injection regimens. This discovery has the potential to transform patient care in the rapidly expanding diabetes and weight management markets [2].

The GLP-1 agonists market is projected to reach $100 billion by 2030, driven primarily by GLP-1 [1]. The market is expected to grow due to advancements in therapies like Tirzepatide and GZR18, which offer both glycemic control and weight loss benefits. The focus on weight management and cardiometabolic health is expected to drive substantial market growth in the coming years.

References:
[1] https://www.goldmansachs.com/insights/articles/anti-obesity-drug-market
[2] https://finance.yahoo.com/news/polypid-unveils-long-acting-glp-120000158.html